International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

[1]  T. Therneau,et al.  Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. , 2014, The Lancet. Haematology.

[2]  E. Colado,et al.  Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. , 2014, Blood.

[3]  R. de Tute,et al.  Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. , 2014, Blood.

[4]  E. Kastritis,et al.  The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma , 2014, Leukemia.

[5]  T. Therneau,et al.  Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey , 2014, Leukemia.

[6]  R. Mick,et al.  Modeling the risk of progression in smoldering multiple myeloma. , 2014 .

[7]  A. Dispenzieri,et al.  CME Information: POEMS Syndrome: 2014 update on diagnosis, risk-stratification, and management , 2014 .

[8]  B. Barlogie,et al.  Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). , 2014, Blood.

[9]  T Hielscher,et al.  Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma , 2014, Leukemia.

[10]  M. Drayson,et al.  Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. , 2014, Blood.

[11]  P. L. Bergsagel,et al.  Smoldering multiple myeloma requiring treatment: time for a new definition? , 2013, Blood.

[12]  O. Landgren.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. , 2013, Hematology. American Society of Hematology. Education Program.

[13]  D. Dingli,et al.  Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Hose,et al.  Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Rajkumar,et al.  Monoclonal gammopathy-associated proliferative glomerulonephritis. , 2013, Mayo Clinic proceedings.

[16]  E. Holmberg,et al.  Treatment for high-risk smoldering myeloma. , 2013, The New England journal of medicine.

[17]  R. Fonseca,et al.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma , 2013, Leukemia.

[18]  F. Prósper,et al.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. , 2013, The New England journal of medicine.

[19]  P. Sonneveld,et al.  Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review , 2013, British journal of haematology.

[20]  M. Dimopoulos,et al.  Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease , 2013, Leukemia.

[21]  A. Dispenzieri,et al.  Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma , 2013, Leukemia.

[22]  R. Braylan,et al.  Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study , 2013, Leukemia & lymphoma.

[23]  O. Landgren,et al.  Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma” , 2013, Leukemia & lymphoma.

[24]  B. Barlogie,et al.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data , 2013, Haematologica.

[25]  A. Dispenzieri,et al.  High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma , 2012, Leukemia.

[26]  E. Nobile‐Orazio,et al.  Neuropathy and monoclonal gammopathy. , 2013, Handbook of clinical neurology.

[27]  J. Cerhan,et al.  Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS , 2013, Leukemia.

[28]  G. Merlini,et al.  Differential diagnosis of monoclonal gammopathy of undetermined significance. , 2012, Hematology. American Society of Hematology. Education Program.

[29]  E. Zamagni,et al.  The role of imaging techniques in the management of multiple myeloma , 2012, British journal of haematology.

[30]  A. Dispenzieri,et al.  Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. , 2012, Blood.

[31]  J. Miguel,et al.  Haematological cancer: Redefining myeloma , 2012, Nature Reviews Clinical Oncology.

[32]  M. Kaminski,et al.  A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.

[33]  D. Dingli,et al.  Trends and outcomes of modern staging of solitary plasmacytoma of bone , 2012, American journal of hematology.

[34]  A. Dispenzieri.  How I treat POEMS syndrome. , 2012, Blood.

[35]  S. Rajkumar.  Preventive strategies in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma , 2012, American journal of hematology.

[36]  A. Dispenzieri,et al.  The pathogenesis and diagnosis of acute kidney injury in multiple myeloma , 2012, Nature Reviews Nephrology.

[37]  Hartmut Goldschmidt,et al.  Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. , 2011, Blood.

[38]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[39]  R. B. Jacobsen,et al.  Diagnosis of Smoldering Multiple Myeloma , 2011 .

[40]  S. Rajkumar,et al.  Development of early treatment strategies for high-risk myeloma precursor disease in the future. , 2011, Seminars in hematology.

[41]  O. Landgren.  Multiple myeloma precursor disease: current clinical dilemma and future opportunities. , 2011, Seminars in hematology.

[42]  W. Kuehl,et al.  Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma , 2010, Leukemia & lymphoma.

[43]  O. Landgren,et al.  Multiple myeloma precursor disease. , 2010, JAMA.

[44]  M. Bøgsted,et al.  Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma , 2010, Cytometry. Part B, Clinical cytometry.

[45]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[46]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[47]  T. Therneau,et al.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study , 2010, The Lancet.

[48]  Tobias Bäuerle,et al.  Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Kyle,et al.  Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. , 2010, Mayo Clinic proceedings.

[50]  A. Órfão,et al.  Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells , 2010, British journal of haematology.

[51]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.

[52]  A. Dispenzieri,et al.  IgM Multiple Myeloma: Disease Definition, Prognosis, and Differentiation From Waldenstrom's Macroglobulinemia. , 2009 .

[53]  P. L. Bergsagel,et al.  Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Rajkumar.  Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance , 2009, Clinical Cancer Research.

[55]  B. Barlogie,et al.  F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. , 2009, Blood.

[56]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[57]  R. Howard,et al.  A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.

[58]  E Terpos,et al.  International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma , 2009, Leukemia.

[59]  M Boccadoro,et al.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders , 2009, Leukemia.

[60]  R A Kyle,et al.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.

[61]  T. Therneau,et al.  Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system , 2008, Leukemia.

[62]  Marina Ruggeri,et al.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders , 2008, Haematologica.

[63]  T. Therneau,et al.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.

[64]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[65]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[66]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[67]  M. Angelopoulou,et al.  Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma , 2007, British journal of haematology.

[68]  B. Barlogie,et al.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Fanin,et al.  A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. , 2007, Haematologica.

[70]  R. Fanin,et al.  A prospective comparison of 18 F-fluorodeoxyglucose positron emission tomography-computed tomography , magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma , 2007 .

[71]  J. Miguel,et al.  New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells. , 2006 .

[72]  T. Therneau,et al.  Immunoglobulin free light chains and solitary plasmacytoma of bone. , 2006, Blood.

[73]  A. Dispenzieri,et al.  Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. , 2006, Mayo Clinic proceedings.

[74]  Allan S. Brett,et al.  Prevalence of Monoclonal Gammopathy of Undetermined Significance , 2006 .

[75]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[76]  M. Dimopoulos,et al.  Macrofocal multiple myeloma in young patients: A distinct entity with favorable prognosis , 2005, Leukemia & lymphoma.

[77]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[78]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[79]  A. Dispenzieri,et al.  Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. , 2005, Clinical chemistry.

[80]  A. Dispenzieri,et al.  Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. , 2005, Clinical chemistry.

[81]  T. Therneau,et al.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.

[82]  E. Giné,et al.  Smoldering multiple myeloma: natural history and recognition of an evolving type , 2003, British journal of haematology.

[83]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[84]  T. Therneau,et al.  POEMS syndrome: definitions and long-term outcome. , 2003, Blood.

[85]  M. Drayson,et al.  Serum test for assessment of patients with Bence Jones myeloma , 2003, The Lancet.

[86]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[87]  S. Montoto,et al.  Monoclonal gammopathy of undetermined significance. , 2006 .

[88]  J. Katzmann,et al.  Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains , 2002 .

[89]  C. Klersy,et al.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[91]  J. Katzmann,et al.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. , 2002, Clinical chemistry.

[92]  T. Therneau,et al.  Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation , 2001, American journal of hematology.

[93]  M. Drayson,et al.  Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. , 2001, Clinical chemistry.

[94]  C. Tinelli,et al.  Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study , 2000, British Journal of Cancer.

[95]  M. Dimopoulos,et al.  Solitary plasmacytoma of bone and extramedullary plasmacytoma. , 1999, Hematology/oncology clinics of North America.

[96]  A. Guermazi,et al.  Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma , 1999, British journal of haematology.

[97]  R. Kyle,et al.  Multiple myeloma associated with diffuse osteosclerotic bone lesions: A clinical entity distinct from osteosclerotic myeloma (POEMS syndrome) , 1997, American journal of hematology.

[98]  M. Dimopoulos,et al.  Prognostic features of asymptomatic multiple myeloma , 1997, British journal of haematology.

[99]  M. Dimopoulos,et al.  Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  E. Holmberg,et al.  Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I — A randomized study , 1993, European journal of haematology.

[101]  M. Dimopoulos,et al.  Risk of disease progression in asymptomatic multiple myeloma. , 1993, The American journal of medicine.

[102]  A. Antela López,et al.  [The POEMS syndrome]. , 1989, Anales de medicina interna.

[103]  A I Pick,et al.  THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.

[104]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.